{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '5. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in', 'the GO-QoL questionnaire VF and A subscale scores.', '6.', 'To evaluate the effect of teprotumumab on the mean change from Baseline to Week 24 in blood and', 'serum markers.', '7.', 'To evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24', 'on the motility component of the Clinical Measures of Severity.', 'Statistical Analysis on Efficacy Parameters', 'The primary analyses will be conducted in the Intent-to-Treat (ITT) population. The analysis of the primary', 'proptosis responder endpoint will assess risk difference (difference in response rates) in a stratified analysis. The', 'analysis will use Cochran-Mantel-Haenszel (CMH) weighting to estimate the common risk difference within', 'strata and to estimate the standard error of the common risk difference. Subjects missing the Week 24 evaluation', 'will be considered to be treatment failures (non-responders) for the primary analysis. Further, subjects who', 'prematurely discontinue study drug dosing prior to Week 21 during the double-masked Treatment Period will be', 'considered to be treatment failures (non-responders), unless an assessment at Week 24 is available. Stratification', 'for the analysis will use the same factor as was used to stratify randomization, tobacco use (non-user, user). The', 'difference in response rates, comparing teprotumumab to placebo, will be estimated along with the', 'corresponding 95% confidence interval (CI) and p-value.', 'An analysis of risk difference with stratification by tobacco use (non-user vs. user) will also be used to analyze', 'the 3 secondary categorical endpoints (overall responder rate, CAS [value of 0 or 1] and diplopia responder', 'rate). For the analysis of proptosis as a continuous secondary endpoint and GO-QoL, a Mixed-Model Repeated-', 'Measures (MMRM) analysis of covariance (ANCOVA) model will be fit to the individual change from baseline', 'scores for the study eye, with terms in the model being the baseline score, tobacco use status, treatment group,', 'visit, and the visit-by-treatment and visit-by-baseline-score interactions. The main focus of the analysis will be', 'to test the treatment differences at Week 24, with the main results consisting of the Week 24 estimated Least', 'Square (LS) means and their differences with 95% CIs and p-values.', 'To control the overall Type 1 error rate of the study, taking into consideration the one primary and 5 secondary', 'outcome measures, the outcome measures will be tested in a hierarchical stepwise fashion. For each outcome', 'measure, teprotumumab will be tested against placebo at the 0.05 level only if teprotumumab was statistically', 'significant for the outcome measure preceding it in the hierarchical order.', 'Sample Size Estimate:', 'In the prior TED01RV study, a 51% difference (71% VS 20%) in proptosis reduction of 2 mm or more between', 'teprotumumab (10 mg/kg for the first infusion followed by 20 mg/kg for the remaining 7 infusions) and placebo', 'was observed at Week 24 in favor of teprotumumab. A sample size of 38 subjects per group provides 90%', 'power at the 2-sided alpha 0.05 level to detect a difference of 39% between teprotumumab and placebo; the', 'sample size has been adjusted to allow for a 16% discontinuation rate.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 28 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '2.1', 'Schedule of Assessments', 'Screening\u00b9', 'Treatment Period 2', 'Follow-Up Period\u00b3', 'Follow-Up', 'Contact4', '11/', '16/', 'Study Visit', 'S1/S2/S3', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '12', '13', '14', '15', 'PW2 6', '17', '18', 'PW15', 'Week (W)/', '-42 to -14', 'Day 17', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W60/', 'W72/', 'W96/', 'W120/', 'Month (M)', 'days', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M42', 'M66', 'Visit Window ( days)', '(=3)', '(+1)', '(=3)', '(+1)', '(+3)', '(=3)', '(+3)', '(+3)', '(=3)', '(=3)', '(+7)', '(+7)', '(+7)', '(+7)', '(+7)', '(=7)', '(+14)', '(+14)', 'Informed Consent', 'X', 'Review inc/exc criteria', 'X', 'Demographics', 'X', 'Medical History 8', 'x9', 'Weight 10', 'X', 'X', 'X', 'X', 'X', 'Randomization 11', 'Study drug infusion', 'Phone (email) contact for safety', 'X', '24 hours postdose 12', 'Efficacy assessments', 'CAS 13', 'X', 'X14', 'X', 'X', 'X', 'X', 'X', 'Clinical Measures of Severity', '- includes proptosis, diplopia', 'X', 'X15', 'X', 'X', 'X', 'and motility restriction', 'Safety assessments', 'Pregnancy Test 16', 'X', 'X', 'X', 'X17', 'Physical exam 18', 'X19', 'X18', 'X', '18', 'X18', 'Ophthalmic exam 20', 'X\u00b21', 'X', 'X', 'Vital Signs 22', 'X', 'X\u00b22', 'X\u00b22', 'X', '12-Lead ECG', 'X', 'X', 'Clinical laboratory tests 23', 'Chemistry (excl. glucose)', 'X24', 'X', 'X', 'X', 'X', 'Thyroid (FT3, FT4, TSH) 25', 'X', 'X', 'X', 'X', 'Hematology', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Glucose 23', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 29 of 117']\n\n###\n\n", "completion": "END"}